Drug
Tildrakizumab
Tildrakizumab: highest development phase Post-Market, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tildrakizumab NCT04339595 | Post-Market | Plaque Psoriasis |
Latest
No recent events.
Follow Tildrakizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.